Contrasting Adult and Pediatric Populations in a Cohort of At-Risk Relatives in The T1D TrialNet Pathway to Prevention Study
Authors' conclusion
Autoantibody positive adult relatives have distinct autoantibody trajectories and progression risks compared with children, suggesting the need for tailored monitoring and intervention strategies.
Study context
- Population
- Relatives of individuals with T1D screened in the TrialNet Pathway to Prevention study
- Participants
- 99,795 vs 135,914
- Exposure
- Adults vs children
- Adultsn = 99,795
- Childrenn = 135,914reference
- Outcome
- Progression to stage 3 T1D, single autoantibody positive
- Follow-up
- 5 years
Methodological detailsscreening of relatives of individuals with T1D
- Screening of relatives of individuals with T1D
Main finding
As reported in the abstract
P < 0.001
Observational data: associations, not effects.
Further findings
Progression to stage 3 T1D, stage 1 T1D · 5 years · lower in adults
P < 0.001
Progression to stage 3 T1D, stage 2 T1D at initial staging OGTT · 5 years
Screen positive for a single autoantibody
Screen positive for multiple autoantibodies · less likely in adults
P < 0.001
Single autoantibody positive among progressors to clinical diabetes · higher in adults
P < 0.0001
Single autoantibody positive among progressors to clinical diabetes
- These adults commonly had single GADA positivity and lower type 1 but higher type 2 genetic risk scores vs multiple autoantibody positive adults
Identification of progressors
- HbA1c and established risk indices more effectively identified progressors in adults vs children
Original publication
Composed by AI from the published abstract and checked against it. How Briefs are made →